Integrating the Latest Therapeutic Advances to Optimize Patient Outcomes in Multiple Myeloma: A Closer Look at the Role of Emerging Therapies and MRD

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2020 to January 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Adaptive Biotechnologies and Sanofi Genzyme

Description:
Multiple myeloma (MM) is a systemic malignancy of plasma cells that is highly treatable but rarely curable. The stage of the disease at presentation is a strong determinant of survival and treatment selection is influenced by the age and general health of the patient, prior therapy, and the presence of complications of the disease. Despite treatment advances in the last several years, MM remains a disease with poor long-term survival as it is currently incurable and all patients will eventually relapse. Fortunately for patients with MM, there are several novel options currently undergoing late stage clinical trials or regulatory review that have shown great promise in their ability to improve clinical outcomes, achieving a minimal residual disease (MRD)-negative response. MRD has emerged as a vital marker for measuring recurrence and improved response rates in numerous hematological malignancies. MRD-based quantification of remaining diseased cells after treatment has been completed, has in recent years been incorporated into many phase three clinical trials across hematologic malignancies as an endpoint for regulatory approval. With the evolving clinical data pool surrounding the quantification of MRD in MM, healthcare professionals who manage patients with hematologic malignancies and managed care professionals who will review approve these options and tests for insurance coverage require targeted education to ensure a thorough understanding of the benefits of setting MRD negativity as a trial endpoint and treatment goal.

Upon completion of this activity, participants will be able to:

  • Analyze recent clinical data on the efficacy and safety of traditional, new, and next-generation therapeutics for patients with relapsed/refractory multiple myeloma

  • Assess the role of emerging anti-CD38 monoclonal antibodies in the relapsed/refractory multiple myeloma treatment paradigm

  • Describe the advantages and limitations of measuring minimal residual disease (MRD)

  • Explore strategies for sequencing treatment for patients with relapsed/refractory multiple myeloma using novel agents

  • Examine the managed care considerations of emerging therapies and MRD-monitoring tests by exploring where these potential agents may fit into current the relapsed/refractory multiple myeloma management paradigm

  • Identify adverse events associated with emerging therapies in relapsed/refractory multiple myeloma, and select appropriate strategies to help ensure patient treatment adherence and optimal quality of life
     

Faculty: Ajay Nooka, MD, MPH, FACP
Associate Professor
Division of Bone Marrow Transplant
Winship Cancer Institute
Emory University

Disclosure:

Dr. Nooka serves on an advisory board for Amgen, BMS, Celgene, GSK, Janssen, Takeda, Spectrum, and Oncopeptides. He has received grant/research support from Amgen, BMS, Celgene, GSK, Janssen, and Takeda. His presentation has been reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
Adaptive Biotechnologies and Sanofi Genzyme

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue